So, here's what's happening with Olema Pharmaceuticals (OLMA) stock. It's having a rough week, and the reason traces back to some news from its much larger pharmaceutical partner, Roche (RHHBY).
Roche released data from a big phase 3 breast cancer study called persevERA. They were testing a drug called giredestrant, combined with another therapy, against a standard treatment. The bottom line? The study didn't hit its main goal. It was looking for a statistically significant improvement in how long patients lived without their cancer getting worse (that's progression-free survival, for the jargon-inclined). The results showed a numerical improvement, which is better than nothing, but it wasn't statistically significant. In the world of drug development, that's a miss.
Why does this matter for little Olema? Because Roche's giredestrant and Olema's lead drug candidate, Palazestrant, are in the same scientific neighborhood. They're both what's known as oral selective estrogen receptor degraders, or SERDs. It's a class of drugs being developed for certain types of breast cancer. When a giant like Roche has a setback in a late-stage trial for a drug in this class, investors in smaller companies working on similar drugs tend to get a bit nervous. It casts a shadow over the whole approach, even if the individual drugs are different.
This is a bit of a role reversal for Olema. Back in November, its stock soared over 200% in a single day after Roche reported positive phase 3 results for giredestrant in a different, earlier-stage breast cancer study. The market was excited about the potential of the drug class, and Olema, with its own candidate, rode that wave up. Now, with a less encouraging result from a different Roche trial, some of that air is coming out of the balloon.
Looking at the stock's technical picture, the mood is bearish in the short term. The stock is trading about 26% below its 20-day moving average and 19% below its 100-day average. That suggests the recent selling pressure has been pretty consistent. Some other indicators are mixed: the Relative Strength Index (RSI) is in neutral territory, but the MACD—a momentum indicator—is in bearish territory. Traders are watching key support around $13.50 and resistance near $22.50.
It's worth keeping the recent drop in perspective, though. Even after this pullback, Olema shares are still up a staggering 294% over the past year. The stock got a massive boost from that earlier Roche news and general optimism about its pipeline. Wednesday's trading saw shares down another 2.5% to around $15.36. So, investors are essentially weighing the long-term promise of Olema's own drug, Palazestrant, against the near-term headwinds created by a partner's clinical stumble.
